Orapred

Ophthalmia, Sympathetic, Collagen Diseases, Uveitis + 12 more
Treatment
24 FDA approvals
20 Active Studies for Orapred

What is Orapred

Prednisolone phosphateThe Generic name of this drug
Treatment SummaryPrednisolone phosphate is a steroid medication used to reduce inflammation and suppress the immune system. It is also used to treat certain types of tumors. The drug was approved by the FDA in 1973 and can produce effects such as constricting blood vessels.
Pediapredis the brand name
image of different drug pills on a surface
Orapred Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Pediapred
Prednisolone phosphate
1986
71

Approved as Treatment by the FDA

Prednisolone phosphate, also called Pediapred, is approved by the FDA for 24 uses such as Conjunctivitis and Uveitis .
Conjunctivitis
Uveitis
Multiple sclerosis exacerbation
Swollen feet or ankles
Dermatological Disease
Endocrine System Diseases
Disease
Ocular Inflammation
Uveitis
Endocrine Disorders
Allergic Conditions
Skin Diseases
Hypersensitivity
Multiple Sclerosis
Ophthalmia, Sympathetic
Temporal Arteritis
Giant Cell Arteritis
Gastroenteritis
Collagen Diseases
Neoplastic Disease
Respiratory Diseases
Uveitis
Edema
Gastrointestinal Diseases

Effectiveness

How Orapred Affects PatientsPrednisolone works by blocking certain signals in the body that can lead to inflammation. It is only active in the body for a short time (2-4 hours), but the amount prescribed can be much higher than what the body makes naturally. People taking prednisolone should be aware of the risk of suppressing the body's hormone system and becoming more vulnerable to infections.
How Orapred works in the bodyCorticosteroids work to reduce inflammation in the body. They do this by affecting the flow of blood vessels and blocking white blood cells from travelling to sites of inflammation. Corticosteroids also change how certain genes are expressed, causing anti-inflammatory effects. Low doses reduce inflammation while high doses weaken the immune system. If taken for a long time, corticosteroids can cause an increase in sodium and decrease in potassium levels.

When to interrupt dosage

The proposed dosage of Orapred is contingent upon the indicated affliction, including Uveitis, Ocular Inflammation and Ophthalmia, Sympathetic. The measure of dosage is set by the method of administration specified in the table below.
Condition
Dosage
Administration
Collagen Diseases
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Swollen feet or ankles
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Respiratory Diseases
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Skin Diseases
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Multiple Sclerosis
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Disease
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Endocrine System Diseases
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Uveitis
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Urinary Tract Infection (UTI)
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Conjunctivitis
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Giant Cell Arteritis
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Gastroenteritis
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Hypersensitivity
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Ophthalmia, Sympathetic
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral
Neoplastic Disease
15.0 mg/mL, , 25.0 mg/mL, 10.0 mg, 15.0 mg, 30.0 mg, 10.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 20.0 mg/mL, 1.0 %, 0.125 %, 0.5 %, 2.3 mg/mL, 1.25 mg/mL
Solution - Oral, , Oral, Solution, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Solution / drops - Ophthalmic, Ophthalmic, Solution / drops, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Liquid; Solution / drops - Ophthalmic, Liquid; Solution / drops, Liquid - Oral

Warnings

Orapred has one contraindication and should not be consummated together with the conditions given in the following table.Orapred Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Prednisolone Phosphate may interact with Pulse Frequency
There are 20 known major drug interactions with Orapred.
Common Orapred Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be decreased when it is combined with Prednisolone phosphate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Prednisolone phosphate.
Aldesleukin
Major
The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Prednisolone phosphate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Prednisolone phosphate.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Prednisolone phosphate.
Orapred Toxicity & Overdose RiskNot much is known about acute Glucocorticoid overdose. Chronic overdose, however, can cause mental symptoms, a round face, fat deposits, and water retention. In case of an acute overdose, the patient should be given their stomach contents to vomit or have it removed with a tube, followed by supportive treatment. If the overdose is chronic, the dose should be reduced temporarily or taken every other day.
image of a doctor in a lab doing drug, clinical research

Orapred Novel Uses: Which Conditions Have a Clinical Trial Featuring Orapred?

115 active clinical trials are currently underway to assess the potential of Orapred to ameliorate Ocular Inflammation, Uveitis and Sympathetic Ophthalmia.
Condition
Clinical Trials
Trial Phases
Uveitis
3 Actively Recruiting
Not Applicable, Phase 3
Giant Cell Arteritis
5 Actively Recruiting
Phase 2, Phase 3
Conjunctivitis
0 Actively Recruiting
Disease
0 Actively Recruiting
Endocrine System Diseases
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4
Multiple Sclerosis
0 Actively Recruiting
Skin Diseases
0 Actively Recruiting
Gastroenteritis
3 Actively Recruiting
Not Applicable
Respiratory Diseases
4 Actively Recruiting
Not Applicable
Collagen Diseases
0 Actively Recruiting
Ophthalmia, Sympathetic
0 Actively Recruiting
Hypersensitivity
0 Actively Recruiting
Neoplastic Disease
1 Actively Recruiting
Phase 1

Orapred Reviews: What are patients saying about Orapred?

4.3Patient Review
6/11/2013
Orapred for Asthma
My daughter experienced some muscle soreness after taking this medication. It was bad enough that it was uncomfortable for her to even be touched.
4Patient Review
1/23/2010
Orapred for Asthma
I've been very pleased with this medication for my child's asthma. They don't become as hyperactive, which was a problem we experienced when using albuterol alone. The only downsides are that they sweat more and have increased appetite/thirst, but those are manageable compared to the benefits.
4Patient Review
5/31/2009
Orapred for Cancer of the Prostate Gland
This cough medicine was really effective for my son.
3.7Patient Review
6/7/2011
Orapred for Vocal Cord Swelling
Orapred has been effective at stopping my son's cough from croup, but he experiences severe side effects like crying and rubbing his eyes and ears obsessively. I'm glad it's only a 3 day course.
3.7Patient Review
11/29/2009
Orapred for Rash
My child became more hyperactive and began to hallucinate about bugs after taking this medication. Even though it got rid of the poison ivy, I would not recommend it for children.
3.3Patient Review
10/29/2008
Orapred for Asthma
My son needed this medication to recover from a severe asthma attack. It's syrup form is quite difficult to get him to take because it likely tastes awful, and he normally does well with taking medicines. As a side effect he's been extremely hyper, has reduced appetite and diarrhea, but this could be due to combination with Albuterol and Pulmicort.
2.7Patient Review
8/11/2009
Orapred for Asthma
My son has ADHD and asthma. When he takes orapred for his asthma, his ADHD becomes much more difficult to control. He is on medication ( focalin) for ADHD and I wonder if the combination of these two drugs creates this type of reaction in other children.
2.3Patient Review
10/18/2009
Orapred for Asthma
My son was on orapred for 5 days. Not only were his moods extremely erratic, but he would vomit in the evening only. Could the vomiting be another side effect? I know nausea can be a side effect, but vomiting too?
2.3Patient Review
9/28/2007
Orapred for Blistering Skin Diseases
I didn't see the results I wanted as quickly as I would have liked. The nurse actually gave me a script and left the room, suggesting I come back if the problem did not improve. Not great service or science!
1.7Patient Review
12/7/2009
Orapred for Bronchitis
It was pretty nightmarish trying to get my seven-month-old to swallow this. I can't imagine why anyone would think that's a reasonable amount for such a young child. We're going to try Veripred tomorrow instead.
1Patient Review
2/22/2009
Orapred for Bronchitis
I believe that one teaspoonful daily is too much for my 9-month-old granddaughter.

Patient Q&A Section about orapred

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Orapred an antibiotic?

"This prescription drug is used to help with swelling that comes from a lot of different illnesses. Some examples of these illnesses are arthritis, joint pain, psoriasis, colitis, leukemia, and allergies."

Answered by AI

Is Orapred a steroid?

"Orapred ODT is a medicine that contains the active ingredient prednisolone, which is a type of medicine known as a corticosteroid. Corticosteroids are medicines that are used to help reduce inflammation in the body."

Answered by AI

Is Orapred the same as prednisone?

"Prednisone and prednisolone are man-made steroids that are similar to cortisol, a hormone that your body produces naturally.

Brand names of prednisone include Prednisone Intensol and Rayos. Brand names of prednisolone include Flo-Pred, Pediapred, Orapred, and Orapred ODT. Prednisone and prednisolone are man-made steroids that are similar to cortisol. Both drugs are used to treat a variety of conditions, including allergies, autoimmune diseases, and skin conditions."

Answered by AI

What is Orapred used for?

"This drug is used to treat a variety of conditions that involve inflammation or an overactive immune system, including arthritis, blood disorders, skin and eye conditions, breathing problems, cancer, and severe allergies. It works by depressing the immune system, which decreases the inflammatory response and relieves symptoms such as pain, swelling, and allergic reactions."

Answered by AI

Clinical Trials for Orapred

Image of Emory University School of Medicine: Division of Rheumatology in Atlanta, United States.

Tocilizumab for Giant Cell Arteritis

18+
All Sexes
Atlanta, GA
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA) patients who are in remission after at least 12 months of high dose TCZ treatment. Eligible participants will also have discontinued glucocorticoids (e.g., prednisone (or equivalent)) entirely at least three months before randomization. High dose TCZ treatment includes 6-8 mg/kg intravenously (IV) monthly or 162 mg subcutaneously (SC) weekly, which are two forms of administration that are commonly used in clinical practice and are equally efficacious in controlling GCA This research study has three parts: 1. The screening phase (up to 42 days) consists of collecting information about your health and your GCA, a physical exam, and blood tests to see If you qualify to enroll in the study 2. The study treatment phase (withdrawal/step down dosing phase study months 0 - 18) consists of you either completely stopping or decreasing your current dose of tocilizumab while collecting information about your health and your GCA as well as blood samples every two months at clinic visits 3. The safety follow-up phase (months 19-30) consists of collecting information about your health and your GCA as well as blood samples every three months The primary objective is to determine the rate of disease relapse at 18 months in participants with GCA who receive low-dose TCZ compared to those who discontinue TCZ
Phase 2
Waitlist Available
Emory University School of Medicine: Division of Rheumatology (+6 Sites)Sebastian H Unizony, M.D.
Have you considered Orapred clinical trials? We made a collection of clinical trials featuring Orapred, we think they might fit your search criteria.Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Have you considered Orapred clinical trials? We made a collection of clinical trials featuring Orapred, we think they might fit your search criteria.Go to Trials
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO
Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.
Phase 4
Recruiting
University of MissouriKevin M Klifto, DO, PharmD
Have you considered Orapred clinical trials? We made a collection of clinical trials featuring Orapred, we think they might fit your search criteria.Go to Trials